Genedrive is a commercial-stage diagnostics company with a mission to deliver rapid, bedside pharmacogenetic testing to enable personalized medicine in time-critical settings. Its core achievement is the successful launch and NHS adoption of its two flagship products: the MT-RNR1 test for neonatal antibiotic safety and the CYP2C19 test for guiding antiplatelet therapy post-stroke. The company's strategy is to leverage its proprietary Genedrive® System platform to expand its test menu, solidify its UK commercial footprint, and pursue international regulatory approvals and partnerships to address a significant global market opportunity in point-of-care genomics.
Infectious Disease (Antibiotic Safety)Cardiovascular/CerebrovascularPersonalized Medicine
Technology Platform
The Genedrive® System is a rapid, simple-to-use point-of-care molecular diagnostic platform that delivers genetic results from a cheek swab or blood sample in approximately 30 minutes using proprietary, room-temperature stable, PCR-based assay chemistry.
Funding History
4
Total raised:$18.7M
Grant$1.2MInnovate UK
Series B$12MUndisclosed
Series A$5MUndisclosed
Seed$500KUndisclosed
Opportunities
The global shift towards personalized medicine and point-of-care testing creates a massive opportunity for rapid pharmacogenetic solutions.
Genedrive's first-mover advantage in critical care settings, validated by NHS adoption, positions it to capture significant value in neonatal care and stroke management, with clear pathways for international expansion and test menu diversification.
Risk Factors
Key risks include commercial execution challenges within the complex NHS procurement system, reliance on a single-payer market (UK), potential delays in international regulatory approvals (e.g., FDA), and future competition from larger diagnostics companies entering the rapid PGx space.
The path to sustainable profitability depends on scaling sales and managing cash burn.
Competitive Landscape
Genedrive's primary competition is from slow, centralized lab-based PGx testing. It faces limited direct competition in the niche of ultra-rapid, bedside pharmacogenetic tests. Its main differentiators are speed (~30 min), extreme ease of use, and a focused approach on acute, actionable drug-gene pairs in emergency care, a segment not currently served by major POC molecular diagnostics companies focused on infectious diseases.
